LONDON (Reuters) -Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes ...
MSF estimates insulin pens can be produced for $0.94 while being profitable; current U.S. price is $90.69. Diabetes affects 537 million globally, with African cases expected to rise by 134% by 2045.
They were eligible if their physician believed that they required insulin therapy ... Denmark] and NovoMix 30 FlexPen® 100 IU/ml suspension for injection in a prefilled pen [Novo Nordisk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback